W

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Business Management
Share
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Source：MarketWatch

Disclaimer：Please read market information rationally and stay aware of investment risks. All content on this site is for informational purposes only and does not constitute investment advice.

Related Reading

Analysts say these chip stocks are bargains. Is it time to buy?

While some analysts view the steep drop in names like Nvidia, Micron and Sandisk as an overreaction, others are staying cautious. Source：MarketWatch

The stock-market rally keeps spreading beyond Big Tech. October inflation data could put it to the test.

Tuesday’s CPI inflation report and a heavy lineup of Federal Reserve speakers could test the rotation trade’s resilience Source：MarketWatch

North Korean hackers create memecoins to launder funds from Binance hack: Elliptic

The blockchain firm traced stolen funds through six new tokens on NEAR, where hackers used liquidity pools to obscure transfers between wallets.…

Formation Securities plans Solana stock trading venue under SEC exemption

The proposed venue would offer 24/7 trading of tokenized shares from Galaxy Digital, Exodus and Forward Industries, with a launch planned for early 2027.…

Source：https://www.marketwatch.com/story/how-ozempic-maker-novo-nordisk-blew-its-lead-in-glp-1-weight-loss-drugs-can-europe-compete-in-the-high-stakes-global-economy-0a2bcfd0